SEC Form 4 · accession 0001209191-18-038277
AGIOS PHARMACEUTICALS, INC. · AGIO
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Kaye I Foster-Cheek
Director
Period of report
Jun 14, 2018
Accepted (ET)
Jun 18, 2018 · 4:05 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001439222
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common stock | Jun 14, 2018 | M | 9,000 | $50.73 | A | 11,200 | D | |
| Common stockF3 | Jun 14, 2018 | S | 2,181 | $92.62 | D | 9,019 | D | |
| Common stockF4 | Jun 14, 2018 | S | 5,980 | $93.78 | D | 3,039 | D | |
| Common stockF5 | Jun 14, 2018 | S | 839 | $94.30 | D | 2,200 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock option (right to buy)F6 | $50.73 | Jun 14, 2018 | M | 9,000 | D | — | Jun 13, 2027 | Common stock | 9,000 | 0 | D |
Explanation of responses
- F1This exercise was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
- F2This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
- F3The price reported is the weighted average of the shares sold. The shares were sold at varying prices in the range of $92.14 to $93.11. The reporting person undertakes, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.
- F4The price reported is the weighted average of the shares sold. The shares were sold at varying prices in the range of $93.15 to $94.13. The reporting person undertakes, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.
- F5The price reported is the weighted average of the shares sold. The shares were sold at varying prices in the range of $94.21 to $94.63. The reporting person undertakes, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.
- F6This option was granted on June 13, 2017. The shares underlying this option vest as to 100% of the underlying shares on June 13, 2018.